Literature DB >> 6184437

Association of certain Ia allotypes with the occurrence of chronic lymphocytic leukemia. Recognition by a monoclonal anti-Ia reagent of a susceptibility determinant not in the DR series.

A Nunez-Roldan, I Szer, T Toguchi, J Cuttner, R Winchester.   

Abstract

The Ia antigen allospecificities of individuals with B type chronic lymphocytic leukemia differed significantly from those of a control population. A monoclonal antibody, IVD12, directed to a MB3-1ike determinant, reacted with 92.5 percent of the individuals with leukemia and yielded the greatest positive relative risk, 13.5. A lower degree of positive association was found with the presence of the MT2 determinant. In contrast, the low observed frequency of the MT1/MB1 determinant among leukemic individuals was associated with the most significant negative relative risk, -8.1. Among HLA- DR specificities, the relative risk associated with the presence of DR5 was positive while that with DR2 was negative.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6184437      PMCID: PMC2186862          DOI: 10.1084/jem.156.6.1872

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  11 in total

Review 1.  The human Ia system.

Authors:  R J Winchester; H G Kunkel
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

2.  Identification of an HLA-DR-associated system of B-cell alloantigens.

Authors:  R J Duquesnoy; M Marrari; K Annen
Journal:  Transplant Proc       Date:  1979-12       Impact factor: 1.066

Review 3.  Histocompatibility systems and disease states with particular reference to cancer.

Authors:  R L Walford; G S Smith; H Waters
Journal:  Transplant Rev       Date:  1971

4.  Human Ia molecules carrying DC1 determinants differ in both alpha- and beta-subunits from Ia molecules carrying DR determinants.

Authors:  G Corte; F Calabi; G Damiani; A Bargellesi; R Tosi; R Sorrentino
Journal:  Nature       Date:  1981-07-23       Impact factor: 49.962

5.  Ia+ T cells in synovial fluid and tissues of patients with rheumatoid arthritis.

Authors:  G R Burmester; D T Yu; A M Irani; H G Kunkel; R J Winchester
Journal:  Arthritis Rheum       Date:  1981-11

6.  Possible HLA role in a family with Hodgkin's disease.

Authors:  A Nuñez-Roldan; F Martinez-Guibelalde; P Gomez-Garcia; C Gomerz-Pereira; G Nuñez-Ollero; A Torres-Gomez
Journal:  Tissue Antigens       Date:  1979-05

7.  Human B-cell alloantigens DC1, MT1, and LB12 are identical to each other but distinct from the HLA-DR antigen.

Authors:  D A Shackelford; D L Mann; J J van Rood; G B Ferrara; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

8.  [Primary structure of class II human histocompatibility antigens. 1st communication. Amino acid sequence of the N-terminal 198 residues of the beta chain of a HLA-Dw2,2;DR2,2-alloantigen (author's transl)].

Authors:  H Kratzin; C Y Yang; H Götz; E Pauly; S Kölbel; G Egert; F P Thinnes; P Wernet; P Altevogt; N Hilschmann
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1981-12

9.  Demonstration of a third structurally distinct human Ia beta chain by two-dimensional gel electrophoresis.

Authors:  R W Karr; C C Kannapell; J A Stein; T C Fuller; R J Duquesnoy; G E Rodey; D L Mann; H M Gebel; B D Schwartz
Journal:  J Exp Med       Date:  1982-08-01       Impact factor: 14.307

10.  Recognition by pregnancy serums of non-HL-A alloantigens selectively expressed on B lymphocytes.

Authors:  R J Winchester; P Wernet; H G Kunkel; B Dupont; C Jersild; S M Fu
Journal:  J Exp Med       Date:  1975-04-01       Impact factor: 14.307

View more
  10 in total

1.  Strong association of rheumatoid arthritis with the presence of a polymorphic Ia epitope defined by a monoclonal antibody: comparison with the allodeterminant DR4.

Authors:  S H Lee; P K Gregersen; H H Shen; A Nunez-Roldan; J Silver; R J Winchester
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

2.  Twenty-six DR beta and 16 DQ beta chain IEF variants and their associated HLA-DR, HLA-DQ, and HLA-Dw specificities.

Authors:  S Rodriguez de Cordoba; P Marshall; P Rubinstein
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

3.  Antigen-specific HLA-restricted human T-cell lines. I. An MT3-like restriction determinant distinct from HLA-DR.

Authors:  E J Ball; P Stastny
Journal:  Immunogenetics       Date:  1984       Impact factor: 2.846

4.  Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi.

Authors:  R A Kalish; J M Leong; A C Steere
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

5.  Definition of a possible genetic basis for susceptibility to acute myelogenous leukemia associated with the presence of a polymorphic Ia epitope.

Authors:  S Seremetis; J Cuttner; R Winchester
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

6.  Further characterization of HLA-DS molecules: implications for studies assessing the role of human Ia molecules in cell interactions and disease susceptibility.

Authors:  S M Goyert; J Silver
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

7.  Acquired congenital heart block. Pattern of maternal antibody response to biochemically defined antigens of the SSA/Ro-SSB/La system in neonatal lupus.

Authors:  J P Buyon; E Ben-Chetrit; S Karp; R A Roubey; L Pompeo; W H Reeves; E M Tan; R Winchester
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

8.  Definition of AML susceptibility and classification using monoclonal antibodies.

Authors:  S Seremetis; J Cuttner; R Winchester
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

Review 9.  Expression of MHC class II antigens in human B-cell leukaemia and non-Hodgkin's lymphoma.

Authors:  K Guy; A S Krajewski; A E Dewar
Journal:  Br J Cancer       Date:  1986-02       Impact factor: 7.640

10.  Molecular localization of human class II MT2 and MT3 determinants.

Authors:  C K Hurley; R C Giles; G Nunez; R DeMars; L Nadler; R Winchester; P Stastny; J D Capra
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 17.579

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.